RecruitingNCT06433752

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Studying Opsoclonus-myoclonus syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
TG Therapeutics, Inc.
Intervention
No Intervention(other)
Enrollment
2000 target
Eligibility
18 years · All sexes
Timeline
2024 – 2032

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06433752 on ClinicalTrials.gov

Other trials for Opsoclonus-myoclonus syndrome

Additional recruiting or active studies for the same condition.

See all trials for Opsoclonus-myoclonus syndrome →

← Back to all trials